SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma

Inclusion Criteria: * Primary open-angle, pseudoexfoliative, or pigmentary glaucoma * Age 21 or over * refractory glaucoma, with IOP \>21 mmHg on medications and failed prior incisional glaucoma surgery * detectable visual field defect (negative MD score) * written consent * available for up to 24 months follow-up Exclusion Criteria: * either eye with VA worse than count fingers * recent angle closure glaucoma episode * uveitic glaucoma, iridocorneal endothelial (ICE) syndrome, traumatic glaucoma, or neovascular glaucoma * other significant ocular disease, except cataract * active ocular infection * expected ocular surgery in next 12 months * no suitable quadrant for implant * systemic corticosteroid therapy \> 5 mg/day prednisone * intolerance to gonioscopy or other eye exams * mental impairment interfering with consent or compliance * pregnancy * known sensitivity to anticipated medications used at surgery * significant co-morbid disease * concurrent enrollment in another drug or device study